These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...

Bayer expects its pharmaceutical business to return to growth in 2027 as the launch new therapies is expected to offset ...

In the US, Janssen booked sales of $549 million in the last quarter, down almost 19% compared with the same period last year, while outside the US Xarelto generated sales of just over $1bn for Bayer.

Growth is on the horizon for German drug conglomerate Bayer (BAYRY), despite “falling sales of its blockbuster blood thinner Xarelto,”amid ...

rivaroxaban (brand name Xarelto) and apixaban (brand name Eliquis). Investigators analyzed nearly 1,000 cases of patients who were treated for a blood clot, also known as venous thromboembolism ...

The research, led by Michigan Medicine, focused on two commonly prescribed blood thinners: rivaroxaban (Xarelto ... decisions about long-term blood thinner use. Dr. Geoffrey Barnes, senior ...

“I believe that this will be proven in the course of the year.” The German group is racing to offset a decline in revenue as blood thinner Xarelto and eye medicine Eylea lose patent protection. This ...

Activist Edward Blum, who challenged affirmative action, has set his sights on college aid.